Clinical Trial Update: Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study evaluating an adenovirus-delivered hepatocyte growth factor for ischemic heart disease, with the current status listed as UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Heart Disease

Drugs mentioned

• Adenovirus Hepatocyte Growth Factor

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Ischemic Heart Disease | Phase 1, Phase 2 | Status: UNKNOWN